Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

RATIONALE: Ensifentrine is a novel, selective, dual phosphodiesterase (PDE)3 and PDE4 inhibitor with bronchodilator and antiinflammatory effects. Replicate phase III trials of nebulized ensifentrine were conducted (ENHANCE-1 and ENHANCE-2) to assess these effects in patients with chronic obstructive...

Descripción completa

Detalles Bibliográficos
Autores principales: Anzueto, Antonio, Barjaktarevic, Igor Z., Siler, Thomas M., Rheault, Tara, Bengtsson, Thomas, Rickard, Kathleen, Sciurba, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449067/
https://www.ncbi.nlm.nih.gov/pubmed/37364283
http://dx.doi.org/10.1164/rccm.202306-0944OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449067/
https://www.ncbi.nlm.nih.gov/pubmed/37364283
http://dx.doi.org/10.1164/rccm.202306-0944OC

Ejemplares similares